Leon Driss, MD
Internal Medicine · Show Low, AZNPI 1669445706
Payments from drug & device makers
Across 227 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sekisui Diagnostics LLC$935
- Novo Nordisk$619
- Flowonix Medical Incorporated$547
- AstraZeneca$538
- GSK$376
- Pfizer$336
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$801%
- Food & beverage$4,19973%
- Education$130%
- Gifts$93516%
- Entertainment$5029%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sekisui Diagnostics LLC | 3 | $935 |
| Novo Nordisk | 23 | $619 |
| Flowonix Medical Incorporated | 2 | $547 |
| AstraZeneca(2 entities) | 35 | $538 |
| GSK | 25 | $376 |
| Pfizer | 21 | $336 |
| Bayer | 12 | $250 |
| Grifols USA, LLC | 11 | $228 |
| Lilly USA, LLC | 14 | $217 |
| AbbVie | 10 | $205 |
| Genentech USA, Inc. | 3 | $194 |
| Boehringer Ingelheim | 8 | $171 |
| Amgen | 6 | $121 |
| Mylan Specialty L.p. | 7 | $113 |
| E.r. Squibb & Sons, L.L.C. | 5 | $105 |
| Johnson & Johnson | 4 | $102 |
| Recordati_rare_diseases_inc. | 4 | $81 |
| Acorda Therapeutics, Inc | 5 | $80 |
| Amarin Pharma, Inc. | 5 | $79 |
| Astellas Pharma US Inc | 4 | $78 |
| Merck | 3 | $49 |
| Collegium Pharmaceutical, Inc. | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Acadia Pharmaceuticals Inc | 2 | $37 |
| Novartis | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Argenx US, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Digestive Care, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Alkermes, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prometra II$502
- XOLAIR$119
- Ozempic$117
- RYBELSUS$111
How this compares
$5,729 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 160 | $201,967 |
| EliquisApixaban | 111 | $150,217 |
| OzempicSemaglutide | 58 | $103,066 |
| JanuviaSitagliptin Phosphate | 43 | $61,793 |
| TrulicityDulaglutide | 23 | $54,910 |
| XareltoRivaroxaban | 44 | $53,891 |
| FarxigaDapagliflozin Propanediol | 38 | $45,129 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $28,324 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $20,112 |
| MyrbetriqMirabegron | 15 | $18,903 |
| Spiriva RespimatTiotropium Bromide | 17 | $17,346 |
| MounjaroTirzepatide | 13 | $15,757 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $13,785 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $13,001 |
| CreonLipase/Protease/Amylase | 11 | $11,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $171 | $227,070192 claims |
| PfizerEliquis | $336 | $150,217111 claims |
| Novo NordiskOzempic | $619 | $103,06658 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $217 | $70,66736 claims |
| AstraZenecaFarxiga, Symbicort | $538 | $65,24288 claims |
| MerckJanuvia | $49 | $61,79343 claims |
| Johnson & JohnsonXarelto | $102 | $53,89144 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $376 | $42,10937 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $18,90315 claims |
| AbbVieCreon, Synthroid | $205 | $13,23358 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Show Low
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
- Franz RischardTucson$3.7M
- Randall SeveranceChandler$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.